Table 1.

FACS^® Analysis of PBLs Comparing CD8⁺ T Cell–depleted with CD8⁺ T Cell–replete HN Groups

		CD8+CD3+ cells/CD3+cells (%)
Group		0 wk*		6 wk‡		12 wk		n
CFA control		23.15 ± 2.20		25.68 ± 1.38		24.63 ± 0.98		3
Normal HN		25.53 ± 2.15		24.43 ± 1.91		25.35 ± 2.05		3
ATx/HN		24.97 ± 0.84		22.14 ± 0.76		21.78 ± 0.77		5
Early CD8 depletion/HN		0.47 ± 0.15§		0.40 ± 0.08§		1.01 ± 0.50§		5
Late CD8 depletion/HN		22.57 ± 0.79		20.17 ± 2.07		1.04 ± 0.40§		5

Prolonged CD8⁺ cell depletion was achieved with ATx followed by anti-CD8 mAb therapy (MRC OX-8). Values represent mean ± SEM, percentage total CD3⁺ cells (G4.18⁺) that are CD8⁺CD3⁺ (MRC OX-8⁺G4.18⁺).  

^* Time of immunization.  

^‡ Before CD8⁺ T cell depletion in group 5.  

^§ P < 0.0001 for comparisons with all CD8⁺ T cell replete groups. ANOVA followed by Bonferroni-Dunn post hoc multiple comparisons test.